Skip to main content
Caris Life SciencesIn development

Caris Life Sciences Reports Third Quarter 2026 Financial Results and Increases 2026 Revenue Guidance

Source: Autobound Signal API · 74 signals tracked for Caris Life Sciences · updated

Get Caris Life Sciences' live signals in Claude or ChatGPT, or by API

AskWhat changed at Caris Life Sciences this week? Use Autobound signals for carislifesciences.com.

What happened

Caris Life Sciences is preparing to launch Caris Confirm, a Whole Genome assay for minimal residual disease, targeted before year-end.

Source

Article excerpt

Highlighted: the sentence this signal was extracted from

Revenue growth of 27% driven by strong performance in molecular profiling services, including approximately 61,500 clinical cases, consisting of over 358,000 total oncology tests Raises 2026 revenue guidance to $1.04 to $1.05 billion, representing growth of 28% to 29% IRVING, Texas, Nov. 4, 2026 /PRNewswire/ -- Caris Life Sciences, Inc. (Nasdaq: CAI ), a leading TechBio company actively developing and commercializing solutions to transform healthcare, today reported financial results for the quarter ended September 30, 2026. Third Quarter 2026 Financial Highlights "This was another record quarter, with approximately 61,500 clinical cases, up 21% year over year," said David Dean Halbert, Founder, Chairman and CEO of Caris Life Sciences. "Every case we run carries real molecular depth, whether Whole Exome, Whole Transcriptome, Whole Genome, or AI-driven digital pathology, and that depth is what allows us to move across the entire cancer journey. Caris Assure ® is now available for therapeutic response monitoring, and Caris Confirm, our Whole Genome, tumor-informed assay for minimal residual disease, is targeted to launch before year-end. It all comes back to making precision medicine a reality for every patient through a comprehensive, data-driven approach." Recent Operating Highlights Third Quarter 2026 Financial Results Total revenue was $275.4 million for the three...

Keep reading with a free account

The rest of this article, and every signal for Caris Life Sciences, is in your free account.

Extracted by Autobound

From the Signal API record
Event
In development

What this signalsWork in development often leads to new buying for tools, data and services.

Product
Caris Confirm
Location
Irving, Texas, United States

The full record

From the Signal API record

Topics and mentions

Product tags

  • medical
  • general technology

Extraction

Confidence
85%
Detected
Nov 4, 2026
signal_type
news
signal_subtype
is_developing

Use this data

Get every in development signal for Caris Life Sciences and the companies you sell to, in the tools you already use.

  1. Ask Claude about it

    Connect Autobound to Claude, Claude Code or Cursor with MCP. Then ask: “What changed at Caris Life Sciences this week?”

  2. Send it to your own tools

    The Signal API returns in development signals for any list of companies as JSON, for your CRM, warehouse or app.

  3. Try it free

    Sign up and spend your free credits on the companies you sell to.

    Start Free1,000 free credits

The API returns more than this page shows

This page shows a preview. The full news record in the Signal API and MCP can also have these 8 fields. Some fields are empty for some signals.

Company

  • linkedin_urlValue in the API
  • industriesValue in the API
  • employee_count_lowValue in the API
  • employee_count_highValue in the API
  • revenueValue in the API
  • descriptionValue in the API

Signal

  • signal_nameValue in the API
  • associationValue in the API
Show the full JSONThe record on this page and the API request

GET /v1/signals/6c3131b5-c8ae-9295-9980-53e4ab122744 returns this record as JSON. POST /v1/companies/enrich returns every signal for carislifesciences.com.

{
  "signal_id": "6c3131b5-c8ae-9295-9980-53e4ab122744",
  "signal_type": "news",
  "signal_subtype": "is_developing",
  "detected_at": "2026-11-04T21:05:00+00:00",
  "company": {
    "name": "Caris Life Sciences",
    "domain": "carislifesciences.com"
  },
  "data": {
    "url": "https://www.prnewswire.com/news-releases/caris-life-sciences-reports-third-quarter-2026-financial-results-and-increases-2026-revenue-guidance-302929429.html",
    "title": "Caris Life Sciences Reports Third Quarter 2026 Financial Results and Increases 2026 Revenue Guidance",
    "excerpt": "Revenue growth of 27% driven by strong performance in molecular profiling services, including approximately 61,500 clinical cases, consisting of over 358,000 total oncology tests Raises 2026 revenue guidance to $1.04 to $1.05 billion, representing growth of 28% to 29% IRVING, Texas , Nov. 4, 2026 /PRNewswire/ -- Caris Life Sciences , Inc. (Nasdaq: CAI ), a leading TechBio company actively developing and commercializing solutions to transform healthcare, today reported financial results for the quarter ended September 30, 2026. Third Quarter 2026 Financial Highlights \"This was another record quarter, with approximately 61,500 clinical cases, up 21% year over year,\" said David Dean Halbert , Founder, Chairman and CEO of Caris Life Sciences. \"Every case we run carries real molecular depth, whether Whole Exome, Whole Transcriptome, Whole Genome, or AI-driven digital pathology, and that depth is what allows us to move across the entire cancer journey. Caris Assure ® is now available for therapeutic response monitoring, and Caris Confirm, our Whole Genome, tumor-informed assay for minimal residual disease, is targeted to launch before year-end. It all comes back to making precision medicine a reality for every patient through a comprehensive, data-driven approach.\" Recent Operating Highlights Third Quarter 2026 Financial Results Total revenue was $275.4 million for the three months...",
    "product": "Caris Confirm",
    "summary": "Caris Life Sciences is preparing to launch Caris Confirm, a Whole Genome assay for minimal residual disease, targeted before year-end.",
    "location": "Irving, Texas, United States",
    "planning": true,
    "image_url": "https://mmx.prnewswire.com/media/MS863020/Caris-Life-Sciences-Logo.jpg?id=OA3056813&p=facebook",
    "confidence": 0.85,
    "product_data": {
      "name": "Caris Confirm",
      "full_text": "Caris Confirm, our Whole Genome, tumor-informed assay for minimal residual disease",
      "fuzzy_match": false
    },
    "product_tags": [
      "medical",
      "general_technology"
    ],
    "published_at": "2026-11-04T21:05:00Z",
    "location_data": [
      {
        "city": "Irving",
        "state": "Texas",
        "region": "Northern America",
        "country": "United States",
        "continent": "Americas",
        "fuzzy_match": false
      }
    ],
    "article_sentence": "\"Every case we run carries real molecular depth, whether Whole Exome, Whole Transcriptome, Whole Genome, or AI-driven digital pathology, and that depth is what allows us to move across the entire cancer journey. Caris Assure ® is now available for therapeutic response monitoring, and Caris Confirm, our Whole Genome, tumor-informed assay for minimal residual disease, is targeted to launch before year-end. It all comes back to making precision medicine a reality for every patient through a comprehensive, data-driven approach.\""
  }
}

Long text fields are shortened on this page.

Looking up one signal by its id is free. Enrich costs 2 credits per signal returned; a call with no results is free.